Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Tax lots affect cost basis and gains in retirement accounts. This piece compares ETFs and mutual funds to help you choose.
25,093 articlesA cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Strategy faces a tough trade-off: use cash to back STRC dividends and buy Bitcoin, or raise fresh capital that dilute...
Lucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
A veteran portfolio manager recounts selling a 19-bagger too early and explains how that misstep reshaped his long-te...
Meta unveils a groundbreaking $145 billion AI infrastructure plan for 2026, signaling a bold pivot from social media ...
Lucid's stock sits near a critical pricing zone as its balance sheet frays and dilution fears mount, even as producti...
The Postmaster General warns the postal service will cash out within 12 months unless Congress lifts the borrowing ca...
Investors are watching novavax (nvax) 2025 earnings closely as the company pivots its vaccine portfolio. This article...
Oklo faces a pivotal moment after July. This piece explains a single catalyst investors should watch, the potential s...
Qualcomm just outlined a much larger growth plan, signaling a strong bet on AI beyond smartphones. This deep dive exp...
Thousands of Americans stranded abroad used private networks and social apps to chart a path back home after regional...
Chevron has kept its promise to shareholders with steady cash returns. Discover how 16 quarters of returns totaling o...